Biblio
HGFK1 Enhances the Anti-Tumor Effects of Angiogenesis Inhibitors via Inhibition of CD90+ CSCs in Hepatocellular Carcinoma. Pharmaceuticals (Basel). 2024;17(5).
RUNX1 together with DAT mutations predicted poor outcome in acute myeloid leukemia. Leuk Lymphoma. 2023:1-11.
.
. .